Asia Pacific Antibiotics Market to Grow at a CAGR of 4.2% to reach US$ 15,784.01 million from 2020 to 2027

The Asia Pacific antibiotics market is expected to reach US$ 15,784.01 millionby2027 from US$ 11,591.97 millionin 2019. The market is estimated to grow with a CAGR of 4.2% from 2020 to 2027.

The growth of the market is driven by factors such as prevalence of infectious diseases and consolidated government initiatives in emerging economies in the Asia Pacific region. However, tedious and expensive process of antibiotic development and the COVID-19 pandemic are likely to restrain the Asia Pacific Antibiotics market growth to a certain extent.

Antibiotics refer to a class of medicines containing substances that are active against bacteria. These medicines either kill the bacteria or control the infection by inhibiting the bacterial reproduction, which in turn helps patient to recover. Antibiotics are specific to the type of bacteria being treated and are not able to be interchanged from one infection to another.

Due to increasing antimicrobial resistance and bacterial infection, there has been rise in efficient and integrated government programs to combat the threat, one of the strategies is One Health approach which provides a coordinated, collaborative, multidisciplinary and cross-sectoral approach in the development of health strategies for people, animals, and the environment. Another boost to the antibiotics market will be the National Health Protection Scheme under Ayushman Bharat, launched in September 2018. Pharma Vision 2020 by the government’s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery which will majorly drive the market in Asia Pacific. India came up with its National Action Plan on Antimicrobial Resistance (2017-21) in April 2017.

Nevertheless, India’s generics market has immense potential for growth. Indian pharmaceutical companies received record 300 generic drug approvals in USA during 2017. Thus, the above factors are likely to drive the growth of antibiotic market duringthe forecast period.

Considering the geographic and economic operations between Asian countries and China, the countries are expected to witness challenge of COVID-19. Domestic startups backed by international funding have already started witnessing back out from investors putting the development of the products in jeopardy. Additionally, the shift from antibiotics clinical trials to COVID-19trails is expected to have negative impact on the introduction of new antibiotics in the market. Such events are potentially projected to have negative impact on growth of antibiotics market in the region.

Rest of Asia PacificAntibiotics Market Revenue and Forecasts to 2027 (US$Mn)

ASIA PACIFICANTIBIOTICS MARKET SEGMENTATION

By Drug Class

• Cephalosporin
• Penicillin
• Fluoroquinolones
• Macrolides
• Carbapenem
• Aminoglycosides
• Sulfonamides
• Others

By Action Mechanism

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors
• Others

By Country

• China
• Japan
• India
• South Korea
• Australia

Companies Mentioned

• GlaxoSmithKline plc
• Sanofi
• Novartis AG
• Astellas Pharma Inc
• Pfizer Inc 

Asia Pacific Antibiotics Report Scope